FLT3 Y572del

CI-VAR-00004826Explore in graph →CIViC 3327

Curated evidence

Evidence by cancer (9 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–9 of 9 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Acute Myeloid Leukemia8
FLT3 Y572del	(oncogenic)	Oncogenic	D	Supports Oncogenicity	4	submitted	EID12858 A pBABE expression vector with wild-type FLT3 was subjected to site-directed mutagenesis to introduce single amnio acid deletions across the juxtamembrane domain then transfected into Ba/F3 cells to c… (full text at CIViC) PMID 33914060 · Young et al., 2021 · Open in CIViC	civic
FLT3 Y572del	Crenolanib	Predictive	D	Supports Sensitivity Response	4	submitted	EID12863 Ba/F3 cell lines expressing the variant FLT3 Y572del showed sensitivity to crenolanib comparable to the FLT3-ITD construct (Figure 4). PMID 33914060 · Young et al., 2021 · Open in CIViC	civic
FLT3 Y572del

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Unmapped disease1unmapped disease
FLT3 Y572del	(functional)	Functional	D	Supports Gain Of Function	5	submitted	EID9305 The construct supported IL-3 independent growth of Ba/F3 cells. It showed FLT-3 autophosphorylation and downstream signaling via STAT5, AKT, and ERK1/2 pathways. With IL-3 deprivation, the cells showe… (full text at CIViC) PMID 33914060 · Young et al., 2021 · Open in CIViC	civic